Among active 13F managers last quarter, 2 opened and 3 added, while 1 reduced; the largest holder to move was Perceptive Advisors LLC (new position). No open-market insider trades in the last 180 days.
Funds lean in and no leg opposes.
16 tracked 13F filers disclose a position in KPRX as of the latest SEC 13F filings, a combined $2.0M in reported value. Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| # | Fund | Shares | Position value | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | Perceptive Advisors LLC | 438K | $1.2M | ▲New +438K sh | Q2 2026 | |
| 2 | ADAR1 Capital Management, LLC | 168K | $324K | —Held | Q1 2026 | |
| 3 | Citadel Advisors LLC | 116K | $305K | ▲+134% Added · +66K sh | Q2 2026 | |
| 4 | Geode Capital Management, LLC | 27K | $70K | ▼−44% Reduced · −21K sh | Q2 2026 | |
| 5 | Vanguard Capital Management LLC | 20K | $52K | —Held | Q2 2026 | |
| 6 | Scientech Research LLC | 19K | $49K | ▲New +19K sh | Q2 2026 | |
| 7 | XTX Topco Ltd | 15K | $28K | ▲+23% Added · +3K sh | Q1 2026 | |
| 8 | Vanguard Fiduciary Trust Co | 13K | $34K | —Held | Q2 2026 | |
| 9 | Caitong International Asset Management Co., Ltd | 2K | $5K | ▲302× Added · +2K sh | Q2 2026 | |
| 10 | Morgan Stanley | 1K | $3K | ▲New +1K sh | Q1 2026 | |
| 11 | UBS Group AG | 1K | $3K | ▲+43% Added · +389 sh | Q1 2026 | |
| 12 | Tower Research Capital LLC (TRC) | 995 | $2K | ▼−37% Reduced · −589 sh | Q1 2026 | |
| 13 | SBI Securities Co., Ltd. | 256 | $673 | —Held | Q2 2026 | |
| 14 | BlackRock, Inc. | 58 | $153 | —Held | Q2 2026 | |
| 15 | Activest Wealth Management | 2 | $5 | —Held | Q2 2026 | |
| 16 | Osaic Holdings, Inc. | 2 | $3 | —Held | Q1 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
Last quarter, 2 funds opened a new position in KPRX and 3 added to an existing one, while 1 reduced. Based on 13F filings from active, signal-eligible managers (passive index funds and other mechanical holders are excluded from this count).
| Company | Co-held by | Their position there |
|---|---|---|
| Invivyd IncIVVD | 8 funds | $24.5M |
| Eli Lilly & CoLLY | 7 funds | $1.2B |
| Praxis Precision Medicines IPRAX | 7 funds | $686.6M |
| Roivant Sciences LtdROIV | 7 funds | $582.4M |
| Unitedhealth Group IncUNH | 7 funds | $516.7M |
| Spyre Therapeutics IncSYRE | 7 funds | $411.4M |
| Boston Scientific CorpBSX | 7 funds | $249.7M |
| Guardant Health IncGH | 7 funds | $227.1M |
| Nuvalent Inc-ANUVL | 7 funds | $207.2M |
| Edgewise Therapeutics IncEWTX | 7 funds | $200.4M |
| Alibaba Group Holding-SP ADRBABA | 7 funds | $199.4M |
| Nurix Therapeutics IncNRIX | 7 funds | $142.4M |
Ranked by how many of KPRX's tracked holders also hold each name. The last column is those co-holders' combined reported position in that name, not in KPRX.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Sep 11, 2024 | Stengone Carmine N. | Director | Buy (P) | 1K | $5K |
| Sep 10, 2024 | Shapiro Aron | Director | Buy (P) | 3K | $11K |
| Aug 19, 2024 | Tyle Praveen | Director | Buy (P) | 5K | $20K |
| Aug 19, 2024 | Walters-Hoffert Lisa | Director | Buy (P) | 1K | $5K |
| Aug 14, 2024 | Tosca Melissa | CFO | Buy (P) | 2K | $6K |
| Jun 14, 2024 | Daniels Eric Joseph | Chief Development Officer | Buy (P) | 1K | $8K |
| Jun 14, 2024 | Tosca Melissa | EVP Finance | Buy (P) | 100 | $525 |
| Jun 13, 2024 | Parsons Erin | Director | Buy (P) | 5K | $26K |
| Jun 13, 2024 | Strem Brian M. | President and CEO, Director | Buy (P) | 3K | $15K |
| Nov 18, 2021 | Strem Brian M. | President and CEO, Director | Buy (P) | 18K | $25K |
| Aug 2, 2021 | Armistice Capital, Llc | 10% Owner | Sell (S) | 193K | $463K |
| Jul 30, 2021 | Armistice Capital, Llc | 10% Owner | Sell (S) | 68K | $183K |
Where institutional funds (13F), corporate insiders (Form 4) and US House members (STOCK Act) are buying or selling the same name in the same window. Green is buying, red is selling.
Insiders and Congress: last 180 days. Funds: latest 13F, top 100 holders incl. passive
| Source | Buying | Selling | Net |
|---|---|---|---|
13F funds Top 100 holders by value, passive included; the hero counts active managers only | 4 | 2 | – |
Insiders Form 4 open-market | 0 | 0 | $0 |
US House STOCK Act trades | 0 | 0 | $0 |
Capital Rotation reports where institutional capital disclosed rotating, as of the latest public SEC 13F filings. It is data, not investment advice, a recommendation, or a prediction. Filings lag about 45 days and cover long US equity positions only. Past disclosed flows do not indicate future prices. Do your own research; consult a licensed advisor.
Connected entities for KPRX
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/KPRX/capital-change-brief"
Use Arkolith's capital_change_brief for KPRX. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for KPRX. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.